Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Prepaid Assets (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Prepaid Assets for 12 consecutive years, with $11.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Prepaid Assets fell 6.42% to $11.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $11.6 million, a 6.42% decrease, with the full-year FY2025 number at $11.6 million, down 6.42% from a year prior.
  • Prepaid Assets was $11.6 million for Q4 2025 at Iovance Biotherapeutics, up from $9.8 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $17.5 million in Q4 2023 to a low of $9.8 million in Q3 2025.
  • A 3-year average of $12.8 million and a median of $11.8 million in 2023 define the central range for Prepaid Assets.
  • Peak YoY movement for Prepaid Assets: dropped 29.1% in 2024, then soared 38.37% in 2025.
  • Iovance Biotherapeutics' Prepaid Assets stood at $17.5 million in 2023, then dropped by 29.1% to $12.4 million in 2024, then decreased by 6.42% to $11.6 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Prepaid Assets are $11.6 million (Q4 2025), $9.8 million (Q3 2025), and $11.5 million (Q2 2025).